TABLE 1.
Participants and virus-specific CD8 T-cell populations studied
| Subject | Sexa | Serologyb |
HSV history and durationc |
HLA typed |
HSV tetramer(s) positive on PBMC ex vivo screening used for ChR studies |
Control tetramerse | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HSV-1 | HSV-2 | Oral | Genital | A | B | HSV-1 type specific | HSV type common | HSV-2 type specific | |||
| HSV T-cell studies only | |||||||||||
| 1 | F | − | + | None | Unk | 03 | 07 | B7-RPR | |||
| 2 | M | − | + | 34.5 | 24.5 | 03,31 | 07,60 | B7-RPR | |||
| 4 | F | + | + | None | 33.5 | 01,26 | 07,08 | B7-RPR | |||
| 6 | M | − | + | None | None | 02,03 | 07,44 | B7-RPR | |||
| 7 | F | − | + | None | 26.5 | 01,02 | 08,13 | A2-FLW | |||
| 9 | M | + | + | Unk | 39.5 | 02,01 | 07,44 | A2-FLW | B7-RPR | ||
| 17 | M | − | + | None | 8.6 | 02,03 | 07,62 | B7-RPR | |||
| 22 | M | + | + | 12.5 | 10.5 | 01,11 | 27 | A1-SAL, A1-FTD | |||
| 25 | F | + | + | 23.5 | 8.3 | 01,31 | 60 | A1-SAL, A1-FTD | |||
| HSV and control T-cell studies | |||||||||||
| 5 | F | + | + | None | 38.4 | 02,11 | 08,15 | A2-FLW | CMV, EBV | ||
| 10 | M | − | + | None | 21.5 | 02,34 | 15,35 | A2-FLW | CMV | ||
| 11 | M | + | + | None | None | 02 | 08,44 | A2-FLW | CMV, EBV | ||
| 14 | F | − | + | None | 9.3 | 02,03 | 07,13 | B7-RPR | EBV | ||
| 16 | M | − | + | None | 12.3 | 02,24 | 07,27 | B7-RPR | EBV | ||
| 26 | M | + | + | None | 8.4 | 02,03 | 07,44 | B7-RPR | EBV | ||
| 28 | F | − | + | None | 12.5 | 03,33 | 07,14 | B7-RPR | CMV, EBV | ||
| Control T-cell studies only | |||||||||||
| 3 | F | − | + | 23 | 25.0 | 01,02 | 08,57 | CMV | |||
| 8 | F | − | + | None | 12.7 | 02,26 | 07,27 | EBV | |||
| 12 | F | − | + | None | Unk | 02 | 27,37 | CMV | |||
| 13 | F | + | + | Unk | 11.5 | 02,26 | 14,27 | EBV | |||
| 15 | F | − | + | None | 20.5 | 02,03 | 14 | CMV, EBV | |||
| 18 | M | + | + | Unk | 17.9 | 02,24 | 35 | CMV | |||
| 19 | M | − | + | 11.5 | 11.5 | 02,31 | 44,64 | EBV | |||
| 20 | F | − | + | None | 38.5 | 02 | 44,62 | CMV, EBV | |||
| 21 | F | + | − | None | None | 01,02 | 07,62 | CMV, EBV | |||
| 23 | F | − | + | Unk | 19.5 | 02,68 | 44,49 | CMV, EBV | |||
| 24 | M | − | + | None | 25.5 | 01,02 | 08,44 | CMV, EBV | |||
| 27 | F | + | − | 51.1 | 6.9 | 02,03 | 07,62 | EBV | |||
a
F, female; M, male.
b
Serostatus by type-specific immunoblot at the closest time point available to the date of blood draw.
c
Years from symptom onset to blood draw. None, no symptoms; Unk, unknown (history not available).
d
HLA class I allele(s) to the two-digit level.
e
Among the control virus-specific populations, the numbers of subjects tested were 11 and 13 for CMV and EBV, respectively, for CLA, 11 and 14 for CCR4, CCR6, CCR7, and CXCR3, 10 and 11 for CCR8, and 10 and 14 for CCR10.